JPRN-jRCT2080223154未知3 期
Phase III clinical study of SUN Y7017 Double blind controlled Study for safety evaluation of 1-step titration with 3-step titration in patients with moderate to severe Alzheimer's disease
试验速览
- 阶段
- 3 期
- 入组人数
- 204
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 50age old 至 <= 85age old(—)
- 性别
- All
入选标准
- •1. Patients with a diagnosis of dementia of the Alzheimer's type based on DSM-IV-TR and probable Alzheimer's disease according to the NINCDS-ADRDA diagnostic criteria.
- •2. Patients with a diagnosis of AD based on brain computed tomography (CT) or magnetic resonance imaging (MRI) within 1 year prior to randomization
- •3. Patients with an MMSE score from 1 to 19 at enrollment
- •4. Patients aged between 50 and 85 years when consent is obtained.
- •5. Patients who are ambulatory without walking aids or with a modest aid such as a walking stick. Patients are also required to have good enough eyesight and hearing to undergo the tests and examinations scheduled in the study (eye glasses or hearing aids can be used)
- •6. Patients whose caregivers are cooperative and reliable enough to manage the study drug, attend study visits with the patient, and check the patient's clinical condition throughout the study period. Patients who will have the same caregiver, in principle, for every study visit throughout the study
排除标准
- •1. Patients with other type of dementia that is not AD
- •2. Patients with Significant neurological disorders
- •3. Musculoskeletal diseases that may hamper conduct of the tests and examinations required in this study
- •4. Any of the following diseases or symptoms
- •1) diastolic pressure >=110 mmHg or systolic pressure <90 mmHg
- •2) Myocardial infarction within 6 months prior to the date of giving informed consent
- •3) Congestive heart failure (NYHA class III or IV )
- •4) Severe renal impairment
- •5) Severe hepatic impairment
- •6) Uncontrolled diabetes mellitus
- •7) Malignant tumor
- •5. A history of alcoholism or drug dependence
- •6. A history of hypersensitivity to any component of memantine hydrochloride
- •7. Planned change of the subject's living environment (admission to a nursing facility, moving house, etc.) during the study period
研究者
相似试验
未知
3 期
A single-blind study of M071754 in patients with infantile spasmsinfantile spasmsJPRN-jRCT2080222507Alfresa Pharma Corporation12
进行中(未招募)
1 期
A single-blind study of M071754 in patients with infantile spasms.EUCTR2017-000230-62-Outside-EU/EEAAlfresa Pharma Corporation and Sanofi KK12
未知
3 期
CS-747S PhaseIII trialJPRN-jRCT2080221302DAIICHISANKYO Co.,Ltd.1,200
未知
3 期
CS-747S PhaseIII trial (elective PCI)JPRN-jRCT2080221511DAIICHISANKYO Co.,Ltd.600
未知
1 期
A randomized, double-blind, placebo-controlled, continuous IV infusion for 96 hours, ascending dose study to assess the safety, pharmacokinetics and pharmacodynamics of CS-4771 in Japanese healthy subjectsHealthy male volunteersJPRN-jRCT2080221894DAIICHISANKYO Co.,Ltd.24
